Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccination in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Zagouri, Flora, Liontos, Michalis, Sklirou, Aimilia D., Koutsoukos, Konstantinos, Markellos, Christos, Briasoulis, Alexandros, Papanagnou, Eleni-Dimitra, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165511/
https://www.ncbi.nlm.nih.gov/pubmed/34059088
http://dx.doi.org/10.1186/s13045-021-01099-x
_version_ 1783701336803508224
author Terpos, Evangelos
Zagouri, Flora
Liontos, Michalis
Sklirou, Aimilia D.
Koutsoukos, Konstantinos
Markellos, Christos
Briasoulis, Alexandros
Papanagnou, Eleni-Dimitra
Trougakos, Ioannis P.
Dimopoulos, Meletios-Athanasios
author_facet Terpos, Evangelos
Zagouri, Flora
Liontos, Michalis
Sklirou, Aimilia D.
Koutsoukos, Konstantinos
Markellos, Christos
Briasoulis, Alexandros
Papanagnou, Eleni-Dimitra
Trougakos, Ioannis P.
Dimopoulos, Meletios-Athanasios
author_sort Terpos, Evangelos
collection PubMed
description Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccination in patients with solid and hematological malignancies under several systemic therapies. The initial results of the cohort of 59 patients receiving Immune Checkpoint Inhibitors are presented here. Despite no new safety issues have been noticed, the levels of SARS-CoV-2 neutralizing antibodies are significantly lower in comparison to matched healthy volunteers up to day 22 post the first dose. These results should be taken into consideration for the patients under treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01099-x.
format Online
Article
Text
id pubmed-8165511
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81655112021-06-01 Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors Terpos, Evangelos Zagouri, Flora Liontos, Michalis Sklirou, Aimilia D. Koutsoukos, Konstantinos Markellos, Christos Briasoulis, Alexandros Papanagnou, Eleni-Dimitra Trougakos, Ioannis P. Dimopoulos, Meletios-Athanasios J Hematol Oncol Letter to the Editor Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccination in patients with solid and hematological malignancies under several systemic therapies. The initial results of the cohort of 59 patients receiving Immune Checkpoint Inhibitors are presented here. Despite no new safety issues have been noticed, the levels of SARS-CoV-2 neutralizing antibodies are significantly lower in comparison to matched healthy volunteers up to day 22 post the first dose. These results should be taken into consideration for the patients under treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01099-x. BioMed Central 2021-05-31 /pmc/articles/PMC8165511/ /pubmed/34059088 http://dx.doi.org/10.1186/s13045-021-01099-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Terpos, Evangelos
Zagouri, Flora
Liontos, Michalis
Sklirou, Aimilia D.
Koutsoukos, Konstantinos
Markellos, Christos
Briasoulis, Alexandros
Papanagnou, Eleni-Dimitra
Trougakos, Ioannis P.
Dimopoulos, Meletios-Athanasios
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
title Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
title_full Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
title_fullStr Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
title_full_unstemmed Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
title_short Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
title_sort low titers of sars-cov-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165511/
https://www.ncbi.nlm.nih.gov/pubmed/34059088
http://dx.doi.org/10.1186/s13045-021-01099-x
work_keys_str_mv AT terposevangelos lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT zagouriflora lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT liontosmichalis lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT sklirouaimiliad lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT koutsoukoskonstantinos lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT markelloschristos lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT briasoulisalexandros lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT papanagnouelenidimitra lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT trougakosioannisp lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors
AT dimopoulosmeletiosathanasios lowtitersofsarscov2neutralizingantibodiesafterfirstvaccinationdoseincancerpatientsreceivingcheckpointinhibitors

Ejemplares similares